Interim data from Bristol-Myers Squibb's BARACLUDE study for chronic hepatitis B patients

Interim data from Bristol-Myers Squibb's BARACLUDE study for chronic hepatitis B patients

News-Medical.net - 1 hour ago
Bristol-Myers Squibb (NYSE: BMY) today announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater ...
BARACLUDE® (entecavir) Demonstrated Greater Antiviral Efficacy Compared to Adefovir in New Study of Chronic Hepatitis B Patients with Evidence of Decompensated Cirrhosis - PharmiWeb.com